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Abstract: Alzheimer′s disease (AD) is the most common age-related neurodegenerative disorder in
which learning, memory and cognitive functions decline progressively. Familial forms of AD (FAD)
are caused by mutations in amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2
(PSEN2) genes. Presenilin 1 (PS1) and its homologue, presenilin 2 (PS2), represent, alternatively,
the catalytic core of the γ-secretase complex that, by cleaving APP, produces neurotoxic amyloid
beta (Aβ) peptides responsible for one of the histopathological hallmarks in AD brains, the amyloid
plaques. Recently, PSEN1 FAD mutations have been associated with a loss-of-function phenotype.
To investigate whether this finding can also be extended to PSEN2 FAD mutations, we studied
two processes known to be modulated by PS2 and altered by FAD mutations: Ca2+ signaling and
mitochondrial function. By exploiting neurons derived from a PSEN2 knock-out (PS2–/–) mouse
model, we found that, upon IP3-generating stimulation, cytosolic Ca2+ handling is not altered,
compared to wild-type cells, while mitochondrial Ca2+ uptake is strongly compromised. Accordingly,
PS2–/– neurons show a marked reduction in endoplasmic reticulum–mitochondria apposition
and a slight alteration in mitochondrial respiration, whereas mitochondrial membrane potential,
and organelle morphology and number appear unchanged. Thus, although some alterations in
mitochondrial function appear to be shared between PS2–/– and FAD-PS2-expressing neurons, the
mechanisms leading to these defects are quite distinct between the two models. Taken together, our
data appear to be difficult to reconcile with the proposal that FAD-PS2 mutants are loss-of-function,
whereas the concept that PS2 plays a key role in sustaining mitochondrial function is here confirmed.
Keywords: Alzheimer′s disease; presenilin 2; PS2–/–; Ca2+ signaling; mitochondria; bioenergetics;
mitochondrial membrane potential; oxygen consumption rate; neuronal hyperexcitability
1. Introduction
About 8% of the world’s population with ages≥65 years are affected by dementia, con-
siderably impacting on global healthcare and social/economic costs. Alzheimer’s Disease
(AD) contributes to the majority of dementia cases and is characterized by a progressive
accumulation of cognitive dysfunctions, partially due to the degeneration of the cholinergic
and glutamatergic systems, which include both altered levels of neurotransmitters and
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disruption of neuronal networks [1]. Most AD cases are sporadic (SAD), while only a
small percentage are genetic and run in families (Familial AD—FAD). The overlapping
phenotype between the two forms allows researchers to exploit FAD mouse models to
study AD pathogenesis and test possible treatments for contrasting the disease.
The FAD-linked mutations are located in the amyloid precursor protein (APP), pre-
senilin 1 (PSEN1) and presenilin 2 (PSEN2) genes, with PSEN1 and PSEN2 mutations
accounting for more than 80% of genetic FAD [2]. Presenilin 1 (PS1) and its homologue pre-
senilin 2 (PS2), constitute, alternatively, the catalytic core of the γ-secretase complex that, by
cleaving APP in concert with β-secretase, produces neurotoxic amyloid beta (Aβ) peptides.
Aβ peptide aggregates form brain extracellular amyloid plaques that, together with intra-
cellular neurofibrillary tangles of hyperphosphorylated tau, represent the histopathological
hallmarks of AD [3].
The mechanism linking FAD mutations to neuronal dysfunction and, ultimately, cell
death is still largely obscure. Importantly, no treatments are available for this pathology
and many clinical trials of drugs targeting Aβ have failed, even though some new drugs
are under investigation [4].
In this complex scenario, the recently proposed hypothesis of a loss-of-function phe-
notype associated with FAD-linked PS1 mutations raises new questions about AD patho-
genesis. In particular, it has been suggested that FAD-PS1 mutations drastically reduce
γ-secretase activity, causing: (i) an overall decrease in the production of Aβ peptides,
despite increasing the Aβ42/Aβ40 ratio, and thus exacerbating Aβ deposition; (ii) memory
impairment and synaptic dysfunction [5].
Considering the similar phenotype characterizing AD patients carrying PS1 or PS2
mutations, as well as SAD patients, and the similar increased Aβ deposition in mouse
models expressing either FAD-PS1 or FAD-PS2 (usually in combination with human FAD-
APP), it is tempting to speculate that if the loss-of-function pathogenic hypothesis is correct
for FAD-PS1 models, it should be also valid for FAD-PS2-linked forms.
In order to address this point at the cellular and molecular levels, we took advantage of
the PS2–/– mouse model [6], knock-out (KO) for PSEN2. Using PS2–/– primary neuronal
cultures, we investigated specific features (Ca2+ homeostasis and mitochondrial function)
previously characterized in FAD-PS2-expressing cells.
As far as cytosolic Ca2+ handling is concerned, we found that PS2–/– neurons, both
cortical and hippocampal, in response to a metabotropic stimulation, are indistinguishable
from wild-type (WT) cells, indicating no alteration in endoplasmic reticulum (ER) Ca2+
content, in contrast to what has been observed in cells expressing FAD-PS2 mutants,
showing, consistently, a reduction in this parameter [7–15]. On the contrary, mitochondrial
[Ca2+] transients, under the same conditions, are significantly reduced in PS2–/– cells,
mainly due to a substantial reduction in the physical apposition between the ER and
mitochondria. Moreover, we observed that PS2–/– neurons display a slight reduction in
mitochondrial respiration, only partially resembling some mitochondrial features found
in FAD-PS2-expressing neurons [16,17]. Similarly, the absence of PS2 is associated with
neuronal hyperexcitability, as already showed for a FAD-PS2 mutant [12]. Altogether, these
observations demonstrate that, although PS2–/– neurons present some features shared
with FAD-PS2-expressing neurons, the mechanisms leading to these phenotypes, at least for
the mitochondrial one, are clearly distinct. Our data indicate that the mitochondria-related
phenotypes associated with FAD-PS2 mutations are not linked to a protein loss-of-function
and suggest that PS2 plays key and multiple roles in controlling mitochondrial function.
2. Materials and Methods
2.1. Animals
All procedures were conducted in accordance with the Italian and European Com-
munities Council Directive on Animal Care and were approved by the Italian Ministry
of Health. Handling of animals was in accordance with Directive 2010/63/EU of the
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European Parliament on the protection of animals used for scientific purposes, with the
explicit approval of the local veterinary authority (Project code: D2784.N.HEH).
2.2. Primary Neuronal Cultures
Primary neuronal cultures were obtained from cortices or hippocampi, dissected
from 0- to 1-day-old newborn mice as previously described [12]. The transgenic mouse
line PS2–/– was used (Infrafrontier, Monterotondo Scalo, Rome, Italy). The line has the
background strain of C57BL/6 mice, which were used as WT controls (Charles River,
Wilmington, MA, USA).
Mouse line features:
• (1) The PS2–/– are homozygous deficient mice, where the PSEN2 gene was inactivated,
replacing the mouse PS2 exon 5 with hygromycin cassette under the control of the
PGK promoter [6];
• (2) The C57BL/6J WT mice share >90% genetic background of the other line.
Cells were seeded on coated coverslips (poly-L-lysine, 100 µg/mL for cortical; poly-
L-lysine 30 µg/mL and laminin 2 µg/mL for hippocampal neurons) with the following
densities:
• 3 × 105 cells/well, for colocalization experiments;
• 8 × 105 cells/well for FRET experiments;
• 3 × 105 cells/well for Seahorse experiments;
• 8 × 105 cells/well for tetramethyl rhodamine methyl ester (TMRM) experiments;
• 1.5 × 106 cells/well for Western Blot and Nonyl Acridine Orange (NAO) experiments.
This was performed in MEM (Gibco, 32360026, ThermoFisher Scientific, Waltham,
MA, USA) containing glucose (20 mM), L-glutamine (0.5 mM), B27 supplement (0.5%), N2
supplement (1%), pyruvic acid (1 mM), biotin (3.6 µM), penicillin (25 µg/mL), streptomycin
(25 µg/mL), neomycin (50 µg/mL) and horse serum (10%). Twenty-four hours after plating,
the medium was replaced with serum- and antibiotic-free with BME (Gibco, 41010026)
supplemented with B27 (2%), L-glutamine (0.5 mM) and sodium pyruvate (0.23 mM). All
the experiments were performed at 14–16 days in vitro (DIVs).
2.3. Adeno-Associated Virus (AAV) Production
Recombinant AAV vectors used in this study were prepared by the AAV Vector Unit at
the International Center for Genetic Engineering and Biotechnology Trieste (http://www.
icgeb.org/avucore-facility.html), as described previously [18] with a few modifications.
Briefly, infectious recombinant AAV vector particles were generated in HEK293T cultures in
roller bottles by a cross-packaging approach whereby the vector genome was packaged into
AAV capsid serotype-9 (AAV9) [19]. Viral stocks were obtained by PEG precipitation and
CsCl2 gradient centrifugation [20]. The physical titer of recombinant AAVs was determined
by quantifying vector genomes (vgs) packaged into viral particles, by real-time PCR against
a standard curve of a plasmid containing the vector genome [21]; values obtained were in
the range of 1 × 1012 to 1 × 1013 vg per milliliter.
2.4. Ca2+ Imaging
Neurons were infected with AAV9-human-synapsin (hSyn)-4mtµ+16 or AAV9-hSyn-
D3mCerulean3+16 and the experiments were performed 7 days after transduction. Cortical
or hippocampal neurons (DIVs 14–16) expressing FRET probes were analyzed using a
DM6000 inverted microscope (Leica, Wetzlar, Germany) and a 40 x oil objective (HCX Plan
Apo, NA 1.25). Excitation light, produced by a 405 nm LED (Led Engin #LZ1-00 UA00
LED), was filtered at the appropriate wavelength (425 nm) through a band pass filter, and
the emitted light was collected through a beam splitter (OES s.r.l., Padua, Italy) (emission
filters HQ 480/40M (for CFP) and HQ 535/30M (for YFP); dichroic mirror 515 DCXR). All
filters and dichroics were from Chroma Technologies (Bellow Falls, VT, USA). Images were
collected using an IM 1.4C cool camera (Jenoptik Optical Systems, Jena, Germany) attached
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to a 12-bit frame grabber. Synchronization of the excitation source and the camera was
performed through a control unit run by a custom-made software package, Roboscope
(developed by Catalin Dacian Ciubotaru at VIMM, Padua, Italy). During the experiments,
cells were mounted into an open-topped chamber and kept at 37 ◦C. Images were acquired
every 1 s, with 300 ms exposure, for KCl and metabotropic stimulation experiments. Images
were acquired every 500 ms, with 300 ms exposure, for picrotoxin stimulation experiments.
Neurons were infected with AAV9-hSyn-4mtGCaMP6f and the experiments were
performed 7 days after virus addition. Cortical neurons (DIVs 14–16) expressing 4mtG-
CaMP6f probes were analyzed using 40× objectives (Olympus Biosystems GmbH, Planegg,
Germany) on an Axiovert 100 inverted microscope (Zeiss, Jena, Germany). Alternated exci-
tation wavelengths of 470 and 410 nm were obtained by a monochromator (Polychrome V,
TILL-Photonics) controlled by Roboscope. The emitted fluorescence was measured at
500–530 nm. Images were acquired every 5 s, with a 300 ms exposure time at 470 nm and
500 ms at 410 nm, by a PCO SensiCam QE camera (Kelheim, Germany) controlled by the
same software. Regions of interest (ROIs), corresponding to the entire soma, were selected
for Ca2+ imaging.
Cells were perfused with mKRB (in mM: 140 NaCl, 2.8 KCl, 2 MgCl2, 10 Hepes,
1 CaCl2, 5 glucose; pH 7.4 at 37 ◦C) supplemented as detailed below.
• In Ca2+ experiments, upon metabotropic stimulation, neurons were perfused with:
(1) mKRB, 60 s; (2) mKRB supplemented with EGTA (600 µM) for 20 s; (3) mKRB
supplemented with CPA (20 µM), carbachol (500 µM); glutamate (100 µM) and ATP
(100 µM).
• In Ca2+ experiments upon KCl stimulation, neurons were perfused with: (1) mKRB,
60 s; (2) mKRB supplemented with KCl (30 mM) for 170 s; (3) mKRB supplemented
with EGTA (600 µM) for 200 s. KCl stimulation was performed in a modified mKRB
to maintain the osmolarity. In particular, the KCl-based mKRB solution contains, in
mM: 110 NaCl, 30 KCl, 2 MgCl2, 10 Hepes, 1 CaCl2, 5 glucose; pH 7.4 at 37 ◦C.
• In picrotoxin Ca2+ experiments, upon picrotoxin stimulation, neurons were continu-
ously perfused with mKRB supplemented with picrotoxin (25 µM) for 100 s.
• In Ca2+ experiments, to evaluate mitochondrial resting Ca2+ level with 4mtGCaMP6f,
3–5 fields of view per coverslip were imaged for 1 min, keeping cells at 37 ◦C and in
mKRB supplemented with 1 mM CaCl2.
Pseudocolor images have been generated using ImageJ. Briefly, the plugin image cal-
culator has been used to create ratio images and then the lookup table function “spectrum”
has been used to create the pseudocolor images.
2.5. Oxygen Consumption Rate (OCR) and Extracellular Acidification Rate (ECAR) Measurements
Cortical neurons were seeded in 500 µL of BME medium (see above) in XF24 cell
culture microplates (Seahorse Bioscience, Agilent, Santa Clara, CA, USA). At DIVs 14–16,
the medium was replaced with 670 µL of seahorse medium (DMEM D5030 supplemented
with, in mM: 1 sodium pyruvate; 5 glucose; 0.031 NaCl, 0.5 glutamine; pH 7.4 at 37 ◦C).
Cells were incubated at 37 ◦C for 1 h, and then OCR and ECAR were measured with an
XF24 Extracellular Flux Analyzer (Seahorse Bioscience). After OCR baseline measurement,
specific drugs were added as indicated (oligomycin-A, 1 µg/mL); carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP, 0.5 µM, defined after titration); rotenone (1 µM)
and antimycin A (0.1 µM). Both the OCR and extracellular acidification rate (ECAR) were
considered.
The classical “mitochondrial stress test” protocol was performed as previously de-
scribed [22]. After calculation of the buffering power of the experimental saline and the
proton rate production [23], mitochondrial and cytosolic (glycolytic) ATP production rates
were calculated from OCR and ECAR measurements as described previously [24].
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2.6. Preparation of Protein Extracts and Western Blot Analysis
At DIVs 14–16, primary cortical neurons were washed once with PBS and collected,
using a cell scraper, in RIPA buffer [in mM: 50 Tris, 150 NaCl; 1% Triton X-100, 0.5% deoxy-
cholic acid, 0.1% SDS, protease and phosphatase inhibitor cocktails (Roche), pH 7.5]. Cells
lysates were incubated on ice for 30 min, centrifuged at 13,000× g for 15 min at 4 ◦C and
the supernatant was collected. Proteins concentration was measured using a BCA assay kit
(EuroClone, Pero, Milan, Italy). In total, 40 µg of protein was loaded onto polyacrylamide
gels (8, 12, 15%) and immunoblotted as previously described [25]. After overnight primary
antibody incubation, secondary species-specific horseradish peroxidase (HRP)-coupled
antibodies (BioRad) were used.
The proteins were visualized by the chemiluminescent reagent ECL (Amersham, GE
Healthcare, Chicago, IL, USA) or LiteAblot TURBO (EuroClone, Pero, Milan, Italy) on
an Uvitec Mini HD9 (Eppendorf, Milan, Italy) apparatus. The intensity of the bands was
analyzed using the ImageJ 1.3 (National Institutes of Health) software program.
Actin, tubulin and heat shock protein 90 (HSP90) protein levels were used as loading
controls. Isotype-matched, HRP-conjugated secondary antibodies (Bio-Rad, Hercules, CA,
USA) were used for detection (GE Healthcare). Different housekeeping proteins have been
used as loading controls in order to find a molecule with a suitable molecular weight for
each blot, depending on the target protein detected on the specific membrane.
2.7. TMRM Experiments
Mitochondrial membrane potential (∆Ψm) was detected using the fluorescent dye
tetramethyl rhodamine methyl ester (TMRM).
Primary cortical neurons (DIVs 14–16) were incubated for 30 min at 37 ◦C in mKRB
supplemented with 1 mM CaCl2 or in a modified experimental saline that includes 10 mM
NaCl and 130 mM K+-gluconate in the absence of CaCl2. K+-gluconate dissipates the
plasma membrane (PM) potential (∆V), minimizing the contribution of ∆V to the TMRM
signal [26,27]. Two different protocols of TMRM loading have been used: (1) 10 nM TMRM
was used in mKRB supplemented with 1 mM CaCl2 supplemented 2 µg/mL cyclosporin H
(CsH) to inhibit multidrug-resistance pumps, which could affect TMRM loading; (2) 20 nM
TMRM (always in the presence of 2 µg/mL CsH) was used to compensate for the K+-
gluconate induced loss of ∆V.
TMRM fluorescence was recorded using 40× objective (SFluor 40× N.A. 1.3, Nikon,
Minato, Tokyo, Japan) on an inverted microscope (Nikon Ti-E). Fluorescence illumination
used a 50–75 W Lamp (USHIO UXLS50A) and 550 nm excitation wavelengths was obtained
using a monochromator (Optoscan CAIRN-Research, Faversham, UK) controlled by NIS-
ELEMENTS AR (Nikon) software. The emitted fluorescence was collected using an FF-570-
Di01Dichroic (Semrock, Lake Forest, IL, USA) and a 620/52 nm (Semrock) filter. Images
were acquired every 60 s, with 50 ms exposure times at each wavelength, by a Zyla-CMOS
4.2-P (Andor, Oxford Instruments, Belfast, Northern Ireland). Where indicated, rotenone
(1 µM) or antimycin-A (1 µM) were added. At the end of each experiment, 10 µM FCCP
was added to assess the correct distribution of the dye. Images were exported as TIFF, and
the background was subtracted and analyzed with ImageJ (National Institutes of Health).
Data are presented as F%, meaning that fluorescence values have been normalized to
final (after FCCP addition) and initial (basal) fluorescence. Pseudocolor images have been
generated using ImageJ, employing the lookup table function “spectrum”.
2.8. Immunofluorescence (IF) and Confocal Analysis
Cortical neurons (DIVs 14–16) infected with AAV-hSyn-4mtD3mCerulean3+16 or
AAV9-hSyn-split-GFP-based contact site sensor (SPLICSs) were first washed with PBS
(once) and then fixed in 4% PFA in PBS supplemented with 0.1 g/mL sucrose. After
15 min in PFA, cells were washed 3 times (3 × 5 min) in PBS and then quenched 20 min
with NH4Cl (50 mM in PBS). Non-infected neurons were stained for cytochrome c for
mitochondrial morphology analysis. After the fixation and quenching step, they were
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permeabilized for 3 min with 0.1% Triton X-100 in PBS and blocked with a PBS solution
containing 2% BSA, 10% goat serum and 0.2% gelatin for 30 min. Cells were incubated
with primary antibodies diluted in blocking solution (dilution for cytochrome c 1:200) for
1.5 h at RT and washed three times (3 × 5 min) with the blocking solution. Cells were
then incubated for 45 min at RT with AlexaFluor 555-conjugated secondary antibodies
(Life Technologies; 1:300 dilution in blocking solution). Coverslips were washed 3 times
(3 × 5 min) with the blocking solution and then with PBS (10 min); finally, they were
mounted with Mowiol.
Images were collected on a Leica TCS SP5 II confocal system using a WLL white
laser (Leica), equipped with a PlanApo 100× (numerical aperture 1.4 objective). For all
images, the pinhole was set to 1 Airy unit. Confocal microscopy imaging was performed at
1024 × 1024 pixels per image, with a 0.2 Hz acquisition rate. Each channel was collected
independently, and photomultiplier gain was adjusted and maintained among different
experiments to minimize background and avoid saturation. Once acquired, images were
background subtracted and not modified further before analysis. Images were elaborated
with ImageJ (National Institutes of Health).
Mitochondrial-ER colocalization: To count ER–mitochondria contacts, a complete z-stack
of the cell was acquired every 0.42 µm. Z-stacks were processed using Fiji. Images were
first convolved and filtered using the Gaussian Blur filter. A 3D reconstruction of the
resulting image was obtained using the Volume J plugin. Two selected faces of the 3D
rendering were then thresholded and used to count ER–mitochondria contact sites.
Mitochondrial morphology: Mitochondria labelled with anti-cytochrome c antibody
and neuronal staining obtained with NeuroTrace™ 640/660 (Invitrogen, ThermoFisher
Scientific) or expressing the 4mtD3mCerulean3+16 were morphologically analyzed as
described in [28] using the Fiji software [29]. Briefly, the background was subtracted, and a
convolve filter and a mask were applied. Using the software’s analyze particle function,
the circularity, the roundness, the aspect ratio (AR) and perimeter of mitochondria were
calculated to assess mitochondrial morphology. Results are expressed as the average of
values per cell profile.
2.9. Nonyl Acridine Orange (NAO) Staining
NAO staining has been used to measure mitochondrial content in cells. The dye binds
specifically to cardiolipin in mitochondria. Neurons were seeded in a 6-well-plate and
transfected as detailed above. NAO dye (400 nM, Sigma Aldrich, St. Louis, MO, USA)
was added to cells at 14–16 DIVs in mKRB. Cells were stained for 30 min at 37 ◦C, washed
with mKRB, detached mechanically by a soft scraping and suspended in mKRB at the
concentration of 100,000 cells/mL. Mitochondrial mass was assessed by flow cytometry
using the FACS Canto II flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA).
2.10. Drugs
Drugs used: cyclopiazonic acid (CPA, Abcam biochemical ab120300); oligomycin-
A (Sigma Aldrich); FCCP (Sigma Aldrich, C2920); rotenone (Sigma Aldrich, R8875);
antimycin-A (Sigma Aldrich, A8674); glutamate (Sigma Aldrich, G1251); ATP (Sigma
Aldrich, A2383); carbachol (Sigma Aldrich, C4382); picrotoxin (Sigma Aldrich, P1675).
2.11. Antibodies
Antibodies used: anti-PS1 (Calbiochem, 529592); anti-cytochrome c (Cell signaling
Technology, 12963, Danvers, MA, USA); anti-hexokinase 1 (HK1,ThermoFisher Scien-
tific, #MA5-14789); anti-mitochondria pyruvate carrier 1 (MPC1, D2L9I, Cell signaling
Technology, 14462); anti-mitochondria pyruvate carrier 2 (MPC2, D4I7G, Cell signaling,
Technology 46141); anti-OXPHOS (Oxidative Phosphorylation) MitoProfile (MS604, Mito-
Sciences, Eugene, OR, USA); anti-tubulin (Santa Cruz Biotech, Dallas, TX, USA, sc-53646);
anti-actin (Sigma-Aldrich, A4700); anti-Lactate Dehydrogenase A (LDHA, Novus Biologi-
cals, NBP1-48336, Milan, Italy); anti-HSP90 (BD Bioscience, BD610418, San Jose, CA, USA);
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anti-Glucose transporter 3 (Glut3, Abcam, EPR20508, Cambridge, UK); anti-cyclophilin D
(Abcam, ab11024); anti-Mitofusin2 (MFN2, Abcam, ab50838); anti-Mitofusin1 (MFN1, Santa
Cruz Biotech, sc166644); anti-Translocase Of Outer Mitochondrial Membrane 20 (TOM20,
Santa Cruz Biotech, FL-145); anti-mitochondrial Ca2+ uniporter (MCU, HPA016480, Sigma-
Aldrich); anti-mitochondrial Na+/Ca2+ (NCLX, Invitrogen, PA5-101901).
2.12. Statistical Analyses
All data are representative of at least 3 different cultures. Data were analyzed using
Origin 7.5 SR5 (OriginLab Corporation, Northampton, Massachusetts, USA) and ImageJ
(National Institutes of Health). Significance was calculated by unpaired Student’s t-test
for normally distributed data or Wilcoxon rank-sum test for data not following normal
distribution (* = p < 0.05, **=p < 0.01, *** = p < 0.001). Unless otherwise specified, numerical
values presented throughout the text refer to mean ± SEM.
3. Results
3.1. Ca2+ Handling in PS2–/– Neurons
3.1.1. Cytosolic Ca2+ Handling in PS2–/– Neurons
Cytosolic Ca2+ responses were evaluated in primary cortical neuronal cultures from
WT and PS2–/– newborn mice. Since PS1 and PS2 can have differential effects on cell
Ca2+ handling (revised in [30]), and a coregulation of PS1 and PS2 expressions has been
previously reported [5,31], we firstly assessed PS1 expression level in WT and PS2–/–
cortical neurons finding a slight increase, although nonsignificant, in this protein in the
absence of PS2 (Figure S1A).
At 7 DIVs, neurons were transduced with an AAV9 (see Materials and Methods),
carrying a newly generated cytosolic FRET-based Ca2+ probe, the D3mCerulean3+16 [32],
under the control of the human-synapsin (hSyn) [33] promoter, to express the indicator
exclusively in neurons.
Resting cytosolic Ca2+ levels in cortical neurons (used at 14–16 DIVs) were indis-
tinguishable in the two genotypes (Figure 1A), as reported in FAD-PS2-expressing neu-
rons [34]. Neurons were then challenged, in the absence of external Ca2+ (to avoid interfer-
ence from Ca2+ influx), with a mixture of metabotropic stimuli in the presence of a SERCA
pump blocker (see legend of Figure 1 and Materials and Methods). The obtained cytosolic
Ca2+ rise was again unchanged between the two genotypes (Figure 1B,C). Similarly, in
PS2–/– hippocampal neurons, the resting cytosolic Ca2+ level (Figure S1B) and the cytosolic
Ca2+ rise elicited by Ca2+ mobilization from the stores (Figure S1C,D) do not show any
significant differences compared to those observed in WT cells. This phenotype differs
from that observed in FAD-PS2-expressing neurons, characterized by a marked reduction
in this parameter [12].
Furthermore, the cytosolic Ca2+ increase in response to a depolarizing stimulus (KCl)
was also very similar in PS2–/– and control cells (Figure 1D,E), as previously reported
in neurons from FAD-PS2 transgenic (tg) mice [12]. It is noteworthy, however, that the
recovery phase of the KCl-induced cytosolic Ca2+ increase was significantly slower in
PS2–/– cortical neurons, compared to that in WT cells (Figure 1F). This feature could be
due to multiple reasons, such as diverse expression/modulation of voltage-operated Ca2+
channels (VOCCs), differences in the PM ∆V, in the level of Ca2+ buffering proteins or in
the Ca2+ efflux pathways. Further investigations will be needed to clarify this issue. Of
note, this alteration in cytosolic Ca2+ handling emerges in PS2–/– neurons only when a
considerable amount of Ca2+ enters the cell, as elicited by a depolarizing stimulus, while it
is not observed upon metabotropic cell stimulations.
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Figure 1. The lack of presenilin 2 (PS2) does not markedly alter the cytosolic Ca2+ handling, but 
induces neuronal hyperexcitability. (A) Left. The cytosolic resting [Ca2+] is visualized employing a 
pseudocolored scale that starts from blue-purple, low [Ca2+], and turns to yellow-red, high [Ca2+], as 
shown by the calibration bar. Right. The bar graph shows the mean basal R ± SEM, as a percentage 
of wild-type (WT), obtained in WT (gray, n = 67 cells of 10 independent cultures) or PS2–/– (red, n = 
104 cells of 9 independent cultures) cortical neurons. (B) Average traces of cytosolic Ca2+ kinetics in 
WT (black) or PS2–/– (red) cortical neurons expressing the cytosolic Ca2+ probe D3mCerulean3+16, 
bathed in mKRB and exposed to a mix of drugs [500 µM carbachol (CCH), 100 µM glutamate, 100 
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Figure 1. The lack of presenilin 2 (PS2) does not markedly alter the cytosolic Ca2+ handling, but
r al erexcitability. (A) Left. The cytosolic resting [Ca2+] is visualized employing a
c l sc l t t st rts fr l e- r le, lo [Ca2+], and turns to yellow-red, high [Ca2+], as
shown by the calibration bar. Right. The bar graph shows the mean basal R ± SEM, as a percentage
of wild-type (WT), obtained in WT (gray, n = 67 cells of 10 independent cultures) or PS2–/– (red,
n = 104 cells of 9 independent cultures) cortical neurons. (B) Average traces of cytosolic Ca2+ kinetics
in WT (black) or PS2–/– (red) cortical neurons expressing the cytosolic Ca2+ probe D3mCerulean3+16,
bathed in mKRB and exposed to a mix of drugs [500 µM carbachol (CCH), 100 µM gluta ate, 100 µM
ATP and 20 µM cyclopi zonic acid (CPA)], after 20 s of EGTA (0.6 mM)-containing mKRB perf sion.
Data are shown as mean ± SEM of ∆R⁄R0 obtained in WT (n = 31 cell of 4 independent cultures) or
PS2–/– (n = 35 cells of 3 independent cultures) cortical neurons. (C) Left. The cytosolic Ca2+ peak
is visualized as described in panel A. Right. The bar graph shows the mean ± SEM of cytosolic
Ca2+ peak amplitude, as a percentage of WT, obtained in WT (gray) or PS2–/– (red) cortical neurons.
(D) Average traces of cytosolic Ca2+ kinetics in WT (black) or PS2 /- (red) cortical neurons expressing
the cytosolic Ca2+ prob D3mCerulean3+16, bathed in mKRB and then perfused in KCl (30 mM)-
containing iso-osmotic aline. Dat are shown as m an± SEM of ∆R⁄R0 obtained in WT (n = 36 cells of
6 independent cultures) or PS2–/– (n= 69 cells of 6 independent cultures) cortical neurons. (E,F) The
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bar graph shows, as a percentage of WT, obtained in WT (gray) or PS2–/– (red) cortical neurons, the
mean ± SEM of (E) cytosolic Ca2+ peak amplitude and of (F) the recovery phase slope (calculated
as linear fit of the first 30 s of the decay phase). * p < 0.05, The cytosolic Ca2+ peak is visualized
in panel E Left as described in panel A. (G) Representative traces of cytosolic Ca2+ kinetics in WT
(left) or PS2–/– (right) cortical neurons expressing the cytosolic Ca2+ probe D3mCerulean3+16 and
stimulated by picrotoxin (25 µM) application in mKRB. The bar graph shows the mean ± SEM of (H)
frequency, calculated as average number of Ca2+ spikes per minutes, *** p < 0.001; (I) peak duration,
** p < 0.01; (J) peak area (arbitrary units, a.u.), ** p < 0.01; (K) peak amplitude, as a percentage of
WT, obtained in WT (gray, n = 132 cells of 5 independent cultures) or PS2–/– (red, n = 131 cells of
5 independent cultures) cortical neurons challenged with picrotoxin.
3.1.2. Neuronal Hyperexcitability in PS2–/– Neurons
Another FAD- and SAD-related phenotype is the neuronal hyperexcitability [35–37].
We previously demonstrated that, in cortical neurons and hippocampal slices from FAD-PS2
tg mice, B6.152H (double tg PS2N141I/APPSwe [38]) and PS2.30H (single tg PS2N141I [39])
mice, the frequency of neuronal Ca2+ spikes, induced by picrotoxin application, were
increased, compared to those present in WT animals, without differences in the peak
amplitude of each spike [12].
Because spontaneous Ca2+ activity is rare in cultured neurons, we exploited the same
protocol to investigate neuronal excitability in PS2–/– cortical neurons. The addition of
picrotoxin, by inhibiting GABA-A receptors, induced synchronous Ca2+ spikes in cortical
neurons (Figure 1G), that were increased in frequency (Figure 1H) and reduced in peak
duration (Figure 1I) and area (Figure 1J) in PS2–/– cells, compared to WT, without any
effect on the peak amplitude (Figure 1K), thus resembling the hyperexcitability phenotype
previously observed in cortical neurons from B6.152H and PS2.30H mice [12]. As previously
shown, picrotoxin-induced cytosolic Ca2+ spikes were generated by glutamate-dependent
activation of AMPA and NMDA receptors, upon the removal of the inhibitory action of
GABA-A receptors. The overlapping picrotoxin-dependent overlapping phenotype found
in FAD-PS2-expressing [12] and PS2–/– neurons (this work) might indicate an inhibitory
role of endogenous PS2 with regard to the glutamate receptors. This function could be lost
when PS2 is mutated. Further in-depth studies are, however, necessary to demonstrate this
hypothesis.
3.1.3. Mitochondrial Ca2+ Handling in PS2–/– Neurons
We have previously demonstrated that FAD-PS2 mutations cause a reduction in
mitochondrial Ca2+ uptake in response to inositol trisphosphate (IP3)-generating stimuli
because of the lower ER Ca2+ content in cells expressing the PS2 mutants [11–13]. On the
other hand, the expression of the same FAD-PS2 mutants induces an increase in the physical
apposition between ER and mitochondria [11–13,17,40], potentiating organelle Ca2+ cross-
talk. Indeed, FAD-PS2 has been shown to be enriched at sites of close proximity between
ER and mitochondria, at specific ER membrane domains, called mitochondria-associated
membranes (MAMs) [13,41].
We thus tested cortical neurons from WT and PS2–/– mice for their mitochondrial
Ca2+ responses by infecting them, at 7 DIV, with an AAV9 carrying a newly generated
mitochondrial FRET-based Cameleon probe, the 4mtD3mCerulean3+16 [32], expressed
under the control of the hSyn promoter. As for the cytosol, mitochondrial Ca2+ experiments
were performed at 14–16 DIVs.
No difference between WT and PS2–/– cortical neurons was observed in the resting
mitochondrial Ca2+ levels (Figure 2A). Since the Kd for Ca2+ of the used probe is 6.5 µM [32]
and Ca2+ concentration ([Ca2+]) in the mitochondrial matrix at rest is in the nm range,
another mitochondrial genetically encoded Ca2+ indicator (GECI) with higher Ca2+ affinity,
4mtGCaMP6f [42,43], was also used to measure resting mitochondrial [Ca2+], confirming
our results (Figure S2A).
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Neurons were then stimulated with the mixture of metabotropic stimuli used before
(Figure 1), in the presence of a SERCA pump blocker and in the absence of external
Ca2+ [12]. A significant reduction in mitochondrial Ca2+ peaks (Figure 2B,C) was observed
in PS2–/– neurons, compared to WT cells, although the cytosolic response to the same
stimulation was indistinguishable (Figure 1B,C). Similar results were also observed in
PS2–/– hippocampal neurons (Figure S2B–D). It is noteworthy that the lack of PS2 and the
expression of FAD-PS2 mutants have similar overall effects on mitochondrial Ca2+ handling
in response to Ca2+ mobilization from the ER [11–13,17]. However, in PS2–/– neurons,
cytosolic Ca2+ peaks observed upon ER Ca2+ release were unaffected with respect to control
cells (Figure 1B,C and Figure S1C–D), while those observed in FAD-PS2-expressing cells
were significantly reduced [7–15].
To investigate whether the observed defective mitochondrial Ca2+ response in PS2–/–
neurons was caused by a reduced ER to mitochondria Ca2+ shuttling (due, for example,
to an increased distance between the two organelles) and/or by an overall mitochondrial
impairment, cortical neurons were stimulated with KCl (30 mM) to induce a large Ca2+
influx across the PM. Mitochondrial Ca2+ uptake was also slightly reduced in PS2–/– neurons
upon this stimulation (Figure 2D,E), although to a lesser extent when compared to the
metabotropic stimulation protocol (Figure 2B,C and Figure S2C,D). Of note, the rate of Ca2+
efflux due to the KCl stimulation was slower in PS2–/– cells, compared to that in controls
(Figure 2F), resembling what was observed in the cytosol (Figure 1F).
Overall, these results suggest that the KO of PS2 causes an impairment in mitochon-
drial Ca2+ handling, as was the case with the expression of FAD-PS2 mutants [11–13,17],
although by mechanisms not related to the content of the intracellular Ca2+ stores.
3.1.4. ER–Mitochondria Apposition in PS2–/– Neurons
As mentioned above, an increased ER–mitochondria proximity was found in cell lines,
neurons and patient-derived fibroblasts carrying different FAD-PS2 mutations [11–13,40].
An increased (or decreased) tethering between the two organelles could allow the forma-
tion of more (or less) microdomains of high [Ca2+], the so-called Ca2+ hotspots, on the
mitochondrial surface, close to the mouth of ER-located Ca2+-releasing channels, thus
favoring (or reducing) mitochondrial Ca2+ uptake for similar IP3-generated cytosolic Ca2+
rises [11,44–46].
To investigate whether ER–mitochondria proximity was modified in PS2–/– neurons,
and thus involved in the defective mitochondrial Ca2+ phenotype observed in these cells,
we took advantage of a recently generated probe, called the split-GFP-based contact site
sensor (SPLICS [40]). This probe allows the detection of organelle contact sites, exploiting
the split-GFP approach. By this methodology, it has been shown that patient-derived
fibroblasts carrying the FAD-PS2-NI141I mutation presented double the number of contact
sites between ER and mitochondria compared to control cells [40], confirming the higher
organelle proximity observed previously when using other methods in the same fibrob-
lasts [11,13] and in neurons from both B6.152H and PS2.30H mice [12]. WT and PS2–/–
cortical neurons were infected with specific AAV9 to express the SPLICS probe under
the control of the hSyn promoter (Figure 2G). Confocal z-stack images of WT and PS2–/–
neurons showed ER–mitochondria contact sites as fluorescent dots (Figure 2G), that were
significantly decreased in number in PS2–/– neurons compared to WT cells (Figure 2H),
according to what we previously showed in SH-SY5Y cells in which PS2 protein level was
reduced by a specific siRNA [11].
Thus, PS2–/– neurons show a marked decrease in ER–mitochondria contact sites, the
opposite of what is consistently observed in FAD-PS2 mutant-expressing cells [11–13,40].
3.2. Mitochondrial Functionality in PS2–/– Neurons
3.2.1. Mitochondrial Morphology and Mass in PS2–/– Neurons
Mitochondrial morphology was assessed by staining the mitochondrial network with
an anti-cytochrome c antibody in cells identified as neurons by NeuroTrace™ (Figure S3A).
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No significant differences were found between controls and PS2–/– neurons in regard
to mitochondrial morphology and organelle numbers (Figure S3A–E). Similar results
were obtained in neurons infected with AAV-hSyn-4mtD3mCeruelan3+16 (Figure S3F–J),
indicating that the infection procedure (and the expression of an exogenous mitochondrial
protein) does not modify the organelle network.
Furthermore, no significant differences were found in the expression levels of different
proteins located at either the inner mitochondrial membrane (IMM), e.g., the mitochondrial
Ca2+ uniporter (MCU, Figure 3A) and the mitochondrial Na+/Ca2+ exchanger (NCLX,
Figure 3B), the outer mitochondrial membrane (OMM), e.g., the translocase of the outer
membrane 20 (TOM-20, Figure 3C), mitofusin 2 (MFN2, Figure 3D) and mitofusin 1 (MFN1,
Figure 3E), or the mitochondrial matrix, e.g., cyclophilin-D (Cycl D, Figure 3F).
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duplicate. The corresponding scatter plot represents the mean values ± SEM. Values were first
normalized to their internal housekeeping proteins (as indicated) and then to those of WT sam-
ples. (A–G) Representative Western blot and quantification of: (A) mitochondrial Ca2+ uniporter
(MCU) protein levels of 6 independent cultures from WT mice and 5 independent cultures from
PS2–/– mice; (B) NCLX protein levels of 4 independent cultures from WT mice and from PS2–/–
mice; (C) TOM20 protein levels of 4 independent cultures from WT mice and from PS2–/– mice;
(D) MFN2 protein levels of 14 independent cultures from WT mice and 8 independent cultures
from PS2–/– mice; (E) MFN1 protein levels of 4 independent cultures from WT mice and from
PS2–/– mice; (F) cyclophilin D (cycl D) protein levels of 4 independent cultures from WT mice and
3 independent cultures from PS2–/– mice. (G) The bar graph shows the mean values ± SEM of
Nonyl Acridine Orange (NAO) fluorescence (arbitrary units) from 4 independent cultures from WT
mice and 3 independent cultures from PS2–/– mice, as a percentage of WT.
Moreover, mitochondrial mass was further estimated by cardiolipin staining combined
with flow cytometry quantification [17]. As shown in Figure 3G, no significant differences
in this parameter were detected between WT and PS2–/– cortical neurons.
Taken together, these results indicate that neither mitochondrial mass nor organelle
morphology are modified by the lack of PS2 expression.
3.2.2. Mitochondrial Membrane Potential
We have previously shown that mitochondria of hippocampal neurons from PS2.30H
mice depolarize faster upon complex I inhibition [17], and mitochondria of cortical neurons
from B6.152H mice undergo a stronger depolarization upon the application of low concen-
trations of the uncoupler FCCP [16], suggesting a mitochondrial dysfunction in neurons
from both FAD-PS2 tg animals.
Since mitochondrial Ca2+ uptake strongly depends on organelle membrane potential
(∆Ψm), the effect of PS2 absence on organelle polarization was investigated by TMRM, a
cell-permeant cationic dye that accumulates inside the mitochondrial matrix as a function
of ∆Ψm.
Neurons were first challenged with rotenone, a specific inhibitor of complex I (Figure 4A),
and no difference between PS2–/– and WT cells was observed in the TMRM fluorescence
decay (Figure 4B). Antimycin A, a complex III blocker, was then used (Figure 4C), and the
mitochondrial depolarization in the PS2–/– genotype was not significantly different to
controls (Figure 4D).
Since TMRM accumulation within mitochondria depends on dye concentration in
the cytosol, and thus on the PM ∆V, to exclude a possible contribution of ∆V, TMRM
measurements were also performed in a K+-gluconate-containing medium. Under these
experimental setting, ∆V is close to 0. Additionally, in this condition, no differences in
TMRM fluorescence kinetics were observed in response to rotenone (Figure S4A,B) or
antimycin A (Figure S4C,D) between PS2–/– neurons and controls.
Finally, the expression level of the respiratory chain complexes and of ATP synthase
were indistinguishable between PS2–/– and WT neurons (Figure 4E), as also reported for
cortical neurons from PS2.30H [17] and B6.152H [16] mice.
3.2.3. Mitochondrial Respiration, Glycolysis and ATP Production
We have previously shown that the maximal oxygen consumption rate (OCR) of
hippocampal neurons from PS2.30H mice is lower compared to that of WT cells [17].
Similar results have been obtained in cortical neurons from B6.152H mice. In this latter
FAD-PS2 mouse model, a reduced spare capacity and cell respiratory control ratio have
been also described [16].
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Figure 4. The lack of PS2 does not aff t ∆ m and the expression levels of the different r spi-
ratory chain complexes. (A–C) Average traces of WT (black) or PS2–/– (red) cortical neurons
loaded with tetra ethyl rhodamine methyl ester (TMRM), bathed in mKRB and exposed to
rotenone (1 µm, panel A) or antimycin A (1 µm, panel C) for 30 min and carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP) (10 µm) for 10 min. Data are shown as mean ± SEM of
F% obtained in WT (rotenone: n = 59 cells of 5 independent cultures; antimycin A: n = 117 cells of
5 independent cultures) or PS2–/– (rotenone: n = 85 cells of 5 independent cultures; antimycin A:
n = 67 cells of 5 independent cultures) cortical neurons. The TMRM fluorescence, at rest, was visual-
ized by employing a pseudocolored scale that starts from blue-purple, low TMRM accumulation, and
turns to yellow-red, high TMRM accumulation (as shown by the calibration bar), in panels A and C
(left part). (B–D) The bar graph shows the mean± SEM of F%, as a percentage of WT, obtained in WT
(gray) or PS2–/– (red) cortical neurons upon rotenone (B) or antimycin A (D) addition, calculated
at the time point indicated by the dashed line of panel (A) or (C), respectively. (E) Representative
Western blot of respiratory chain complexes and ATP synthase levels in WT and PS2–/– neurons.
The scatter plots show the mean values ± SEM of 9 independent cultures for WT and 7 independent
cultures for PS2–/–, run in duplicate. Values were first normalized by their internal HSP90 levels
and then to those of WT samples.
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Mitochondrial respiration was investigated, using the Seahorse platform, in WT and
PS2–/– neurons (Figure 5A–C). To estimate basal and maximal respiration, we performed
two distinct protocols (Figure 5B,C). Indeed, as already reported [16,22,47], the addition
of the uncoupler FCCP after oligomycin prevented the possibility of reaching maximal
OCR in neurons (Figure 5B). Thus, maximal respiration rate was assessed separately from
oligomycin addition by adding increasing concentrations of FCCP (Figure 5C). PS2–/– cells,
compared to controls, have a reduced basal OCR (mainly due to ATP synthesis and proton
leak, Figure 5D), ATP-linked respiration (due to ATP synthase, Figure 5E), maximal OCR
(upon uncoupler addition, Figure 5F) and proton leak (Figure 5G) and a slightly higher
non-mitochondrial oxygen consumption (Figure 5H). However, the ratio between basal
and oligomycin-resistant OCR, called coupling efficiency and equivalent to the classical
“mitochondrial respiratory control”, was indistinguishable in the two cell types (Figure 5I).
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(OCR) experimental protocol. (B–C) OCR mean traces in WT (black) and PS2–/– (red) primary cor-
tical neurons. Oligomycin (Oligo, 1 µM), FCCP (0.5 µM), and antimycin A (0.1 µM) plus rotenone 
(1 µM) were added as indicated. Data are plotted as mean pmol/min ± SEM (n > 45 wells from at 
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neurons. Oligomycin (Oligo, 1 µM), FCCP (0.5 µM), and antimycin A (0.1 µM) plus rotenone (1 µM)
were added as indicated. Data are plotted as mean pmol/min ± SEM (n > 45 wells from at least
6 independent cultures). (D–I) Quantification of OCR measurements in panels B and C. The bar
graph shows the mean ± SEM as a percentage of WT, obtained in WT (gray) or PS2–/– (red) cortical
neurons of: (D) the basal OCR (calculated as differences between initial OCR and OCR after antimycin
A/rotenone addition), ** p < 0.01; (E) the mean ATP-linked OCR (calculated as differences between
initial OCR and OCR after oligomycin addition), * p < 0.05; (F) the mean of the maximal respiratory
capacity (calculated as difference between OCR after FCCP addition and the OCR after antimycin
A/rotenone addition), ** p < 0.01; (G) the mean proton leak (calculated as differences between the
oligomycin-sensitive OCR and OCR after antimycin A/rotenone addition), ** p < 0.01; (H) the mean
non-mitochondrial OCR (OCR remaining after addition of all drugs), * p < 0.05; (I) the mean coupling
efficiency (calculated as ratio between ATP-linked OCR and basal OCR).
The extracellular acidification rate (ECAR, Figure 6A), an indicator of anaerobic
glycolysis, was also calculated from OCR experiments (Figure 5). Increased basal ECAR
(Figure 6B) and maximal glycolysis (Figure 6C) were found in PS2–/– neurons, compared
to WT, while the glycolytic reserve (defined as the difference between ECAR induced by
oligomycin addition and basal ECAR; Figure S5A) presented no differences between the
two genotypes. According to these data, a lower OCR/ECAR ratio was calculated for
neurons lacking PS2 (Figure S5B).
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of WT, obtained in WT (gray) or PS2–/– (red) cortical neurons of: (B) the basal ECAR, *** p < 0.001;
(C) the maximal glycolysis (calculated as mean of the ECAR reached upon oligomycin addition),
** p < 0.01; (D) the total ATP production rate (JATP Prod); (E) the glycolytic ATP production rate
(JATP Glyc), *** p < 0.001; (F) the ATP production rate due to mitochondrial respiration (OXPHOS;
JATP ox), * p < 0.05; (G) the Glycolytic Index (calculated as ratio between normalized JATP Glyc and
JATP), *** p < 0.001.
These results are substantially different from those obtained previously in cortical
neurons from B6.152H mice, in which, compared to WT cells, a decreased basal and
maximal ECAR as well as a reduced glycolytic reserve have been observed [16].
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Using ECAR and OCR data, an indirect estimation of the rate of ATP production
within the cell can be performed [23,24]. According to this calculation, PS2–/– neurons dis-
played no significant difference in total ATP production compared to WT cells (Figure 6D).
However, in PS2–/– neurons, glycolytic ATP was increased (Figure 6E), while oxygen-
linked ATP production appeared partially decreased (Figure 6F), suggesting a modest
metabolic switch towards glycolysis in these cells (Figure 6G).
3.2.4. Key Proteins in the Regulation of Glycolysis, Krebs Cycle and Oxidative
Phosphorylation
To obtain some mechanistic insights into the mitochondrial phenotype found in PS2–/–
neurons, the protein levels of multiple enzymes and transporters linked to mitochondrial
metabolism and bioenergetics were also investigated. In particular, we measured the
protein levels of: (i) hexokinase-1 (HK1), the first enzyme of glycolysis, a key protein that,
by dynamically associating with the mitochondrial protein VDAC, coordinates cytosol-
mitochondria metabolic cross-talk (Figure S6A); (ii) glucose transporter 3 (GLUT3), a
protein specifically devoted to the transport of glucose across the PM in neurons (Figure
S6B); (iii) mitochondrial pyruvate carrier (MPC), MPC1 (Figure S6C) and MPC2 subunits
(Figure S6D), a protein that transports pyruvate into the mitochondrial matrix; (iv) lactate
dehydrogenase (LDH), a key enzyme linking glycolysis and mitochondrial respiration
(Figure S6E).
PS2–/– cortical neurons do not display differences in the total expression levels of these
proteins, compared to WT, similarly to what has been reported in cortical neurons from
B6.152H mice [16], whereas MPC2 has been found to be reduced in FAD-PS2-expressing
cells [17].
4. Discussion
The recently proposed loss-of-function phenotype associated with FAD-PS1 raises a
question about the possibility of extending this pathogenic hypothesis to FAD-PS2-linked
cases, given the overlapping phenotype among AD patients carrying PSEN1 or PSEN2
mutations [5].
FAD-PS2 mutations have been associated with Ca2+ and metabolic dysfunctions
(reviewed in [30,48–50]). In particular, PS2 has been implicated in the modulation of:
(1) SERCA pump activity and thus ER Ca2+ accumulation [10]; (2) ER to mitochondria
Ca2+ shuttling and physical organelle apposition [11–13,40]; (3) mitochondrial bioenerget-
ics [16,17,51,52]. Moreover, evidence has been accumulated suggesting that mitochondrial
dysfunctions are early events in AD pathogenesis, suggesting a “mitochondrial cascade
hypothesis” (reviewed in [53–56]). Most of these data have been obtained in cells or tg
animals overexpressing FAD-PS2, since knockin animals are not available yet. However,
it is worth mentioning that we have previously demonstrated that fibroblasts from FAD
patients, in which the mutated PS2 is not overexpressed resembling the pathological situa-
tion, also share the same phenotype [7,8,10,13,15,40]. Nevertheless, our finding that the
effects of FAD-PS2 mutants on multiple Ca2+ pathways is mimicked by high expression
levels of wt PS2 [7,8,11,15] might have implications for the pathogenesis of SAD, the more
frequently form of the disease, where the reported decreased expression level of Repressor
Element 1-Silencing Transcription factor (REST [57]) causes an increase in the endogenous
PS2 expression [58].
As far as Ca2+ signaling is concerned, we found that PS2–/– neurons show a Ca2+-
related phenotype different from that reported in FAD-PS2-expressing cells, except for the
Ca2+ hyperexcitability. Indeed, PS2-linked FAD mutants have been reported to dampen
ER Ca2+ content and mitochondrial Ca2+ uptake upon IP3-linked stimulation [7–15], while
increasing ER–mitochondria contact sites [11–13,40]. Instead, PS2–/– neurons do not show
alteration in ER Ca2+ release, whereas they display a reduced mitochondrial Ca2+ uptake
in response to Ca2+ mobilization from stores, likely due to a decreased ER–mitochondria
apposition. Indeed, this latter feature appears particularly evident in PS2–/– neurons,
strongly supporting the idea that PS2 is a key regulator of organelle tethering [11–13,40].
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Interestingly, when stimulated by KCl, while the peak in cytosolic Ca2+ is indistin-
guishable in the two genotypes, the decrease in the KCl-induced Ca2+ transient in PS2–/–
cells is slower compared to that observed in control cells. This feature has not been found
in FAD-PS2-expressing neurons [12]. The mechanism of this phenomenon is presently
unclear but confirms that the KO of PS2 and expression of FAD-PS2 mutants have different
effects on neuronal Ca2+ handling. The kinetics of the KCl-induced mitochondrial Ca2+ rise
was very similar in PS2–/– and controls, although a small but significant reduction was
observed in the mitochondrial Ca2+ peak amplitude. No significant differences, however,
were observed in the expression level of the main mitochondrial Ca2+ handling molecular
components, MCU and NCLX proteins. The simplest explanation is that, upon depolar-
ization and activation of VOCCs, the entrance of Ca2+ across the PM triggers the release
of Ca2+ from the ER, via ryanodine receptors, and the reduced apposition of mitochon-
dria to the ER, observed in PS2–/– neurons, results in a decreased ER-to-mitochondria
Ca2+ transfer.
Previous studies unveiled a specific role of PS2 in maintaining mitochondrial function
and cell bioenergetics. Indeed, decreases in ∆Ψm, reduced mitochondrial respiration,
defective mitochondrial cristae morphologies and increased glycolysis have been reported
in mouse embryonic fibroblasts (MEFs) lacking PS2 [51,52]. All these mitochondrial alter-
ations were specifically due to the lack of PS2 since PS1-KO MEFs did not show any of
these phenotypes [51,52]. Although, it is worth mentioning that other works reported a
role of PS1 mutants in mitochondrial impairment [59–62]. Along similar lines, neurons
from FAD-PS2 tg mice showed defective mitochondrial bioenergetics [16,17], according to
the emerging idea of AD as a metabolic pathology, in which an energetic unbalance could
strongly contribute to its genesis [53,63].
Here, we could not confirm the data reported in PS2–/– MEFs (as summarized in
Table 1), as we found that PS2–/– neurons have no defects in mitochondrial morphology
and number, as well as in their ∆Ψm and expression levels of respiratory chain complexes
and ATPase. Instead, PS2–/– neurons show a slight alteration in respiratory parameters
and glycolysis. However, the coupling efficiency (i.e., the ratio between basal OCR and
OCR after oligomycin) is indistinguishable in control and PS2–/– cells.
Likely, the reduced ER-to-mitochondria Ca2+ shuttling, due to the strong decrease in
contact sites between the two organelles observed in PS2–/– neurons, could contribute to
these minor defects in organelle respiration. Indeed, the constitutive, low Ca2+ transfer
between ER and mitochondria has been shown to be important in sustaining optimal
mitochondrial function and cell bioenergetics [46]. Alternative explanations are, however,
possible and further investigations are thus needed to solve this point.
The PS2–/– phenotypes described here are likely due to the specific ablation of PS2,
despite the presence of a slight, nonsignificant, increase in PS1 levels in these animals. In-
deed, we previously demonstrated that PS1 overexpression [11,15], or downregulation [11],
does not affect intracellular Ca2+ handling and ER–mitochondria tethering. Moreover,
acute downregulation of endogenous PS2 [11] induces similar phenotypes compared to
those described here on mitochondria Ca2+ handling and ER–mitochondria apposition
by stable PS2 ablation, thus excluding any genetic compensation-related effect on these
parameters.
To our knowledge, the only work investigating the effect of PS2 ablation on mitochon-
drial functions has been carried out in MEF cells [51,52]. Here, we addressed this issue in
primary neurons, as they represent a relevant cellular model for AD. However, since this is
an in vitro study and, thus, it might have intrinsic limitations, further in vivo investigations
in PS2–/– mice will be needed to extend our knowledge on the effects of PS2 ablation on
brain Ca2+ signaling and mitochondrial function in a more physio-pathological context
and during aging. Nevertheless, up to now, we have found full correspondence between
in vitro and ex vivo data obtained for Ca2+ handling in FAD-PS2-expressing models, as
shown by [12], where the results obtained in primary neurons and in acute hippocampal
brain slices from FAD-PS2 transgenic mice perfectly overlap.
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Table 1. The table summarizes the Ca2+ handling and mitochondrial bioenergetics parameters analyzed in PS2–/–, Familial Alzheimer’s disease (FAD)-PS2 expressing neurons and mouse
embryonic fibroblasts (MEFs) PS2–/–, compared to WT. ND = not determined.
PS2N141I PS2N141I APPswe MEF PS2−/− PS2−/−(This Paper)
Cytosolic Ca2+ handling Basal levels unchanged [32] unchanged [32] ND unchanged
Store Ca2+ content reduced [12] reduced [12] ND unchanged
KCl response unchanged [12] unchanged [12] ND unchanged
Neuronal hyper-excitability increased [12] increased [12] ND increased
MitochondrialCa2+handling Basal levels ND ND ND unchanged
ER–mitochondria Ca2+ transfer reduced [12] reduced [12] ND reduced
KCl response ND ND ND reduced
ER–mitochondria contacts increased [12] increased[12] ND reduced
Mitochondrial morphology unchanged unchanged [16] defective cristae [53] unchanged
Mitochondrial mass unchanged [17] unchanged [16] ND unchanged
Mitochondrial membrane potential Basal unchanged [12] unchanged [12, 16] unchanged [52,53] ND
Complex I inhibition faster decay [17] unchanged [16] ND unchanged
Complex III inhibition ND unchanged [16] ND unchanged
OxygenConsumptionRate (OCR) Basal reduced [17] unchanged [16] reduced [52,53] reduced
Maximal reduced [17] reduced [16] reduced [52,53] reduced
ATP-linked respiration reduced [17] unchanged [16] reduced [52,53] reduced
Proton leak unchanged [17] unchanged [16] ND reduced
Non-mitochondrial OCR unchanged [17] unchanged [16] ND increased
Glycolysis(ECAR) Basal unchanged [17] reduced [16] increased [52,53] increased
Maximal Glycolysis unchanged [17] reduced [16] ND increased
Respiratory chain complexes (levels of expression) unchanged [17] unchanged [16] reduced CI, CII, CIV [53] unchanged
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Moreover, our data might have important therapeutic implications for AD. Indeed, if
the hypothesis proposed by Xia et al. that FAD-PS1 mutations are loss of function was true,
and this could be generally extended to FAD-PS2 mutants as well, a paradigm change in
AD pathogenesis would occur, opening new therapeutic venues aimed at restoring, instead
of at inhibiting, PS functions [5]. This, however, seems not to be fully confirmed, raising
doubts regarding the proposed pathogenic mechanism for AD.
5. Conclusions
The results obtained in neurons KO for PS2 indicate that most of the cellular and
molecular phenotypes described for FAD-PS2 mutations are not recapitulated by the lack
of PS2 (as summarized in Table 1), but rather deletion of PS2 has mainly opposite effects
compared to those induced by the expression of FAD-PS2 mutants. In particular, PS2–/–
neurons have normal ER Ca2+ contents (while FAD-PS2 expression causes a major ER Ca2+
depletion) and show a strongly reduced physical apposition between ER and mitochondria
(while FAD-PS2 reinforces organelle tethering, causing a large increase in these contacts).
Finally, recent investigations of local field potentials in FAD-PS2 and PS2–/– mice showed
that the two models substantially differ in the alterations of their brain network activity
patterns [64,65], providing further evidence against the hypothesis of a loss-of-function
phenotype associated with FAD-PS2 mutants.
The modest alterations in both mitochondrial Ca2+ handling and bioenergetics are
consistent with the fact that PS2–/– mice are alive and healthy without a brain phenotype,
or other defects, until 12 months of age, with the only exception of a mild pulmonary
fibrosis (which is not affecting animal breathing) and the insurgence of hemorrhages with
age. Moreover, a similar apoptosis rate, APP processing and Aβ production have been
found in PS2–/– neurons, compared to WT cells [6]. Instead, the KO of PS1 is embryonically
lethal, indicating that PS1 and PS2 overlap only partially in their functions, with PS1 being
specifically indispensable for embryonic development, mainly affecting the Notch signaling
pathway [66–69].
Taken together, the present data indicate that the majority of the functional effects
of FAD-PS2 mutants are not related to a loss-of-function phenotype and that the ER-
located protein PS2, by modulating the physical and functional coupling between ER and
mitochondria, is an important regulator of cell bioenergetics.
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